<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The impact of thymidylate synthase (TYMS), <z:chebi fb="0" ids="25297">methylenetetrahydrofolate</z:chebi> reductase (MTHFR), and serine hydroxymethyltransferase 1 (SHMT1) gene polymorphisms and that of dihydropyrimidine dehydrogenase (DPD) enzyme activity, serum total <z:chebi fb="0" ids="17230">homocysteine</z:chebi> level, and estimated serum <z:chebi fb="0" ids="16737">creatinine</z:chebi> clearance on first-line <z:chebi fb="0" ids="46345">5-fluorouracil</z:chebi>, leucovorin, irinotecan, and bevacizumab (FOLFIRI+bevacizumab) regimen efficacy in <z:e sem="disease" ids="C0948380" disease_type="Neoplastic Process" abbrv="">metastatic colorectal cancer</z:e> patients was investigated </plain></SENT>
<SENT sid="1" pm="."><plain>DNA was extracted from peripheral blood mononuclear cells </plain></SENT>
<SENT sid="2" pm="."><plain>Genotyping was performed for TYMS 5'UTR variable number tandem repeat, TYMS 3'UTR ins/del, MTHFR C677T, and SHMT1 C1420T polymorphisms </plain></SENT>
<SENT sid="3" pm="."><plain>The DPD activity of peripheral blood mononuclear cells was also determined </plain></SENT>
<SENT sid="4" pm="."><plain>The univariate and multivariate analyses demonstrated that the SHMT1 1420T allele was associated with better response (P=0.025) and longer progression-free survival (PFS) (P=0.00004) and overall survival (OS) (P=0.034) </plain></SENT>
<SENT sid="5" pm="."><plain>Grade â‰¥2 <z:hpo ids='HP_0000822'>hypertension</z:hpo> was also an independent prognostic factor of longer progression-free survival and OS </plain></SENT>
<SENT sid="6" pm="."><plain>Bevacizumab-related <z:hpo ids='HP_0000822'>hypertension</z:hpo> might be a predictive marker of treatment efficacy (P=0.0002 for OS) in the case of wild (CC) SHMT1 1420 genotypes only </plain></SENT>
</text></document>